Exemptia — Adalimumab
Adalimumab was one of the first TNF-alpha inhibitors to reach the market and remains one of the most widely prescribed biologics globally, largely because its prefilled-syringe, self-injectable format gives patients a genuinely different access model compared to the IV-infusion biologics that dominate the rest of our immunotherapy catalogue. That distinction matters directly to distributors evaluating home-care and pharmacy-channel distribution feasibility, not just hospital-based supply.
- Approved indications: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis
- Mechanism: Neutralizes TNF-alpha, a key inflammatory signaling protein driving autoimmune disease activity
- Administration format: Self-injectable prefilled syringe — administered subcutaneously, typically every 1-2 weeks depending on indication
- Distribution implication: Unlike IV-infusion biologics, this SKU is viable for retail pharmacy and home-delivery distribution channels, not just hospital infusion centers
Key Product Facts
20 mg and 40 mg
Strength
1 Prefilled Syringe (S) Of 0.8 ml
Pack Size
Adalimumab
Active Ingredient
Rheumatology
Category
Enquire Now for Pricing
Price
Adalimumab was one of the first TNF-alpha inhibitors to reach the market and remains one of the most widely prescribed biologics globally, largely because its prefilled-syringe, self-injectable format gives patients a genuinely different access model compared to the IV-infusion biologics that dominate the rest of our immunotherapy catalogue. That distinction matters directly to distributors evaluating home-care and pharmacy-channel distribution feasibility, not just hospital-based supply.
- Approved indications: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis
- Mechanism: Neutralizes TNF-alpha, a key inflammatory signaling protein driving autoimmune disease activity
- Administration format: Self-injectable prefilled syringe — administered subcutaneously, typically every 1-2 weeks depending on indication
- Distribution implication: Unlike IV-infusion biologics, this SKU is viable for retail pharmacy and home-delivery distribution channels, not just hospital infusion centers
- Contraindication: Active tuberculosis or severe active infection
- Cardiac caution: Not recommended in moderate-to-severe heart failure
- Vaccination: Live vaccines should be avoided during treatment
- Contraception requirement: Required during treatment and for 5 months following the final dose
- TB screening: Mandatory before initiating treatment, given the elevated reactivation risk with TNF-inhibitor therapy
| Document |
Included |
| Certificate of Analysis (COA) |
Standard |
| Certificate of Origin (COO) |
Standard |
| MSDS |
Standard |
Stock status: In stock for export | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export (2–8°C)
- Coverage: Global export markets
- Distribution flexibility: Suitable for both hospital and retail pharmacy supply chains given its self-injectable format
What is Adalimumab used for?
Treats rheumatoid arthritis, psoriasis, Crohn's disease, and several other autoimmune conditions.
Get Adalimumab price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Can it be self-injected at home?
Yes, it comes as a prefilled syringe designed for patient self-administration after training.
Does it increase infection risk?
Yes — TB screening is required before starting, and patients are monitored for infection risk throughout treatment.
Who supplies Adalimumab from India?
WHO-GMP certified manufacturer with full export documentation.
